Sugi Predict

Sugi Predict / Compounds / SCHEMBL1229307

SCHEMBL1229307

SCHEMBL1229307

COC(=O)c1cc(Br)nc2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.68
▸ MEN1 O00255 8/20 0.58
▸ KMT2A Q03164 8/20 0.58
▸ ALDH1A1 P00352 6/20 0.56
▸ HPGD P15428 3/20 0.56
▸ TDP1 Q9NUW8 3/20 0.56
▸ PKM P14618 2/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ POLB P06746 2/20 0.56
▸ PLIN1 O60240 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ GLA P06280 1/20 0.56
▸ PLIN5 Q00G26 1/20 0.56
▸ MCL1 Q07820 1/20 0.56
▸ ABHD5 Q8WTS1 1/20 0.56
▸ DHODH Q02127 1/20 0.56
▸ L3MBTL1 Q9Y468 3/20 0.56
▸ USP2 O75604 1/20 0.55
▸ MAPT P10636 3/20 0.52
▸ TP53 P04637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14572690 0.88 KDM4E (0.54) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL7487026 0.84 KDM4E (0.68) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL14518623 0.84 MEN1 (0.72) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL31510490 0.84 KDM4E (0.49) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL663977 0.83 KDM4E (0.70) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL31295407 0.83 KDM4E (0.70) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL12903095 0.83 KDM4E (0.70) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL72379 0.83 KDM4E (0.70) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL13209750 0.82 NPC1 (0.48) KDM4EMEN1KMT2ALMNADHODH
SCHEMBL1900912 0.82 KDM4E (0.62) KDM4EMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724430-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE Flagship Pioneering Innovations VI, LLC (US) 2026-04-15 — — EP disclosed
WO-2024254396-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) 2024-12-12 — — WO disclosed
US-8969573-B2 Compounds for the inhibition of cellular proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-03-03 — — US disclosed
US-8969573-B2 Compounds for the inhibition of cellular proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-03-03 — — US disclosed
US-8969573-B2 Compounds for the inhibition of cellular proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-03-03 — — US disclosed
US-20130178505-A1 Compounds for the Inhibition of Cellular Proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-11 — — US disclosed
US-20130178505-A1 Compounds for the Inhibition of Cellular Proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-11 — — US disclosed
US-20130178505-A1 Compounds for the Inhibition of Cellular Proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-11 — — US disclosed
EP-2585453-A2 COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION President and Fellows of Harvard College (US) 2013-05-01 — — EP disclosed
US-20120190701-A1 RENIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-07-26 — — US disclosed
WO-2011020193-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2011-02-24 — — WO disclosed
EP-1333834-B1 ANTIINFLAMMATION AGENTS AMGEN INC (US) 2008-04-23 — — EP disclosed
US-20070135464-A1 Antiinflammation agents AMGEN, INC. 2007-06-14 — — US disclosed
US-7186841-B2 (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders AMGEN INC. (US) 2007-03-06 — — US disclosed
EP-1333834-A4 ANTIINFLAMMATION AGENTS AMGEN INC (US) 2007-01-17 — — EP disclosed
US-20050043330-A1 Antiinflammation agents AMGEN INC. (US) 2005-02-24 — — US disclosed
US-6846834-B2 Compounds contain fused carbocyclic or heterocyclic rings; modulate expression and/or function of proteins involved in inflammation, metabolism and cell proliferation AMGEN INC. (US) 2005-01-25 — — US disclosed
EP-1333834-A2 ANTIINFLAMMATION AGENTS Tularik Inc. (US) 2003-08-13 — — EP disclosed
US-20020161004-A1 Antiinflammation agents SYNTEX (U.S.A.) LLC (US) 2002-10-31 — — US disclosed
WO-2002041843-A2 ANTIINFLAMMATION AGENTS TULARIK INC. (US) 2002-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135464-A1 Antiinflammation agents TNF, NFATC1, NFKBIA KDM4E 4242/4885MEN1 4728/4885KMT2A 4495/4885
US-20050043330-A1 Antiinflammation agents TNF, NFATC1, NFKBIA KDM4E 4242/4885MEN1 4728/4885KMT2A 4495/4885
US-20120190701-A1 RENIN INHIBITORS REN, ACE, AGTR1 KDM4E 3912/4885MEN1 3095/4885KMT2A 4131/4885
US-20130178505-A1 Compounds for the Inhibition of Cellular Proliferation MKI67, EIF2AK2, CDK2 KDM4E 2418/4885MEN1 3017/4885KMT2A 3071/4885
US-20020161004-A1 Antiinflammation agents TNF, NFATC1, NFKBIA KDM4E 4242/4885MEN1 4728/4885KMT2A 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.